Document is current

Article History

Accepted: 6 June 2024

First Online: 2 July 2024

Declarations

:

: SH is the chief scientific officer and is on the board of Phagenesis Ltd., a company involved in neuromodulatory dysphagia treatment. BL has received research funding and/or awards from the German Research Foundation (DFG), the medical faculty of the university of Muenster, the German Society for Geriatrics (DGG)/ the Rolf und Hubertine Schiffbauer Foundation, has received travel support and/or conference reimbursement for presentations from the German Society for Clinical Neurophysiology and Functional Imaging (DGKN), the European Stroke Organisation (ESO), the German Society for Neurology (DGN), the European Society for Swallowing Disorders (ESSD), the United European Gastroenterology (UEG), the German Society for Nutritional Medicine (DGEM), the German Society for Internal Medicine (DGIM) and the university of Zuerich, and has received honoraria for lectures from the German Society for Muscular Diseases (DGM), and from Phagenesis Ltd.. AS, IC, SL, and NR do not have any conflicts of interest. 

: No funding was received by any of the authors for the writing of this paper.

: AS and IC drafted the manuscript, assisted by BL and SL. SH and NR supervised the drafting of the manuscript and contributed to its structure. All authors made contributions to the manuscript and jointly submitted it for publication.

: Not applicable.

: Not applicable.

: Not applicable.